July 15, 2025

New Autism Classes Highlight Genetic Underpinnings

Researchers identified four distinct autism subtypes with unique genetic profiles and developmental patterns.

Conexiant

July 14, 2025

Skin Autoimmune Disorders Tied to Longer Cancer Survival

A large nationwide study in Taiwan found that patients with autoimmune skin diseases had lower all-cause and cancer-specific mortality following cancer treatment compared with those without these conditions.

Conexiant

July 14, 2025

Self-Injection Device Effective for Acne Lesions

A new multicenter trial found that self-injected low-dose triamcinolone using an assistance device was as effective and safe as physician-administered injections for inflammatory acne, with improved outcomes at higher doses for severe lesions.

Conexiant

July 10, 2025

1 in 4 US Infants Missing Bifidobacterium: Study

Babies who lacked this key gut bacteria were at an increased risk of eczema, allergies, and asthma by age 2.

Conexiant

July 09, 2025

Recombinant Zoster Vaccine Linked to New-Onset Lupus

Researchers report the first documented case of systemic lupus erythematosus following Shingrix vaccination.

Conexiant

July 09, 2025

Oral Bacteria Linked to Brain, Gene Risk

A study of older adults found that specific oral bacteria were linked to cognitive performance and genetic risk for Alzheimer’s, while other microbes showed stronger associations in people with mild cognitive impairment.

Conexiant

July 08, 2025

Natural Cycle Beats HRT in FET Outcomes

A randomized trial found that using a natural cycle to prepare the endometrium for frozen embryo transfer in ovulatory women led to higher live birth rates and fewer complications compared to hormone replacement therapy.

Conexiant

July 08, 2025

Does Deprescribing Do More Than Less?

Deprescribing interventions reduce the number of medications taken by older adults but show no clear effect on hospitalization, mortality, or quality of life—and appear to be safe.

Conexiant

July 07, 2025

FDA Approves First Oral Hereditary Angioedema Treatment

FDA approves Ekterly (sebetralstat), the first oral on-demand treatment for hereditary angioedema, shown in trials to provide faster symptom relief and eliminate the need for injection.

Conexiant